Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine

Journal of Infectious Diseases

Volumn 202, Issue 4, 2010, Pages 595-605

  Gilbert, Peter ^a   Wang, Maggie ^a   Wrin, Terri ^b   Petropoulos, Chris ^b   Gurwith, Marc ^d   Sinangil, Faruk ^c   D'Souza, Patricia ^f   Rodriguez Chavez, Isaac R ^f   DeCamp, Allan ^a   Giganti, Mike ^a   Berman, Phillip W ^e   Self, Steve G ^a   Montefiori, David C ^g  

^a Fred Hutchinson Cancer Research Center   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c Global Solutions for Infectious Diseases   (United States)

^d PaxVax Inc   (United States)

^e University of California Santa Cruz   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; DEMOGRAPHY; DRUG DESIGN; FEMALE; HELA CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; PRIORITY JOURNAL; PROTECTION; VACCINATION; VIRUS INFECTION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TYPING;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; NEUTRALIZATION TESTS;

EID: 77954722964     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/654816     Document Type: Article

References (50)

1. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006; 6:930-939
2. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24:227-255
3. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-444.
4. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42.
5. McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS 2000; 14(Suppl 3):S31-44.
6. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol 1996; 70:427-444 (Pubitemid 126508812)
7. Mascola JR, Louwagie J, McCutchan FE, et al. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 1994; 169:48-54.
8. Binley JM, Wrin T, Korber B, et al. Comprehensive crossclade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252 (Pubitemid 39507829)
9. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-2360.
10. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280:1884-1888
11. Yang X, Lipchina I, Cocklin S, Chaiken I, Sodroski J. Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J Virol 2006; 80:11404-11408.
12. Crooks ET, Moore PL, Richman D, et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Human Antibodies 2005; 14:101-113.
13. Moore PL, Crooks ET, Porter L, et al. The nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006; 80:2515-2528.
14. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape. Nature 2003; 422:307-312.
15. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptorbinding sites. Nature 2002; 420:678-682.
16. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15:866-870.
17. Walker LM, Phogat SK, Chan-Hui P-Y, et al. Broad and potent neutralizing antibodies from an African donor reveal new HIV-1 vaccine target. Science 2009; 326:285-289.
18. Mascola JR, Snyder SW,Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboNeutralizing Antibody Response in Vax004 Trial ratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996; 173:340-348.
19. Bures R, Gaitan A, Zhu T, et al. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by gp160 protein boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000; 16:2019-2035.
20. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998; 12:2407-2415.
21. Seaman MS, Janes H, Hawkins N, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessments of neutralizing antibodies. J Virol 2010; 84:1439-1452.
22. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, Norcross MA. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994; 68:6006-6013.
23. Davis KL, Gray ES, Moore PL, et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 2009; 387:414-426.
24. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005; 201:1407-1419.
25. Matthews TJ. Dilemma of neutralization resistance of HIV-1 filed isolates and vaccine development. AIDS Res Hum Retroviruses 1994; 10: 631-632.
26. Moore JP, Burton DR. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med 2004; 10:769-771.
27. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 2006; 124:677-681.
28. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236.
29. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149.
30. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-10125.
31. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa. J Virol 2006; 80:11776-11790.
32. Kulkarni SS, Lapedes A, Tang H, et al. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C human immunodeficiency virus type 1 env clones from India. Virology 2009; 385:505-520.
33. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007; 21:693-702.
34. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7557.
35. Schweighart B, Liu Y, Huang W, et al. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 2007; 46:1-11.
36. Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14:S277-S289.
37. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX- to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14:S325-S331.
38. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-677.
39. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
40. Gilbert PB, Ackers ML, Berman PW, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005; 192:974-983.
41. Berman PW, Huang W, Riddle L, et al. Development of bivalent (B/ E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 1999; 265:1-9.
42. Pitisuttithum P, Gilbert PB, Gurwith M, et al. Randomized, placebocontrolled efficacy trial of a bivalent rgp120 HIV-1 vaccine among injecting drug users in Bangkok, Thailand. J Infect Dis 2006; 194: 1661-1671.
43. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
44. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infection by macrophage tropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-2864.
45. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
46. Lachenbruch PA. Comparison of two-part models with competitors. Statistics in Medicine 2001; 20:1215-1234.
47. Huang Y, Gilbert PB, Montefiori DC, Self SG. Simultaneous evaluation of the magnitude and breadth of a left-and right-censored multivariate response, with application to HIV vaccine development. Stat Biopharm Res 2009; 1:81-91.
48. Pérez-Losada M, Jobes DV, Sinangil F, Crandall KA, Posada D, Berman PW. Phylodynamics of HIV-1 from a phase III AIDS vaccine trial in North America. Mol Biol Evol 2010; 27(2):417-425.
49. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004; 190:1962-1969.
50. Pérez-Losada M, Posada D, Arenas M, et al. Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. Retrovirology 2009;6: 67-69.